Ekulizumab

Iz Wikipedije, slobodne enciklopedije
(Preusmjereno sa Eculizumab)
Idi na navigaciju Idi na pretragu
Ekulizumab
Klinički podaci
Robne marke Soliris, Soliris (Alexion Pharmaceuticals)
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 219685-50-4
ATC kod nije dodeljen
DrugBank DB01257
ChEMBL[1] CHEMBL1201828 YesY
Hemijski podaci
Formula ?
Mol. masa 148 kDa
Farmakokinetički podaci
Poluvreme eliminacije 82 h
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Intravenozno

Ekulizumab (INN i USAN; prodajno ime Soliris) jeste humanizovano monoklonalno antitelo. Ono je prvo u klasi terminalnih inhibitora komplementa, kao i prva terapija koja je odobrena za lečenje paroksizmalne noćne hemoglobinurije (PNH), retke, progresivne, i u pojedinim slučajevima smrtonosne bolesti karakterisane prekomernim uništavanjem crvenih krvnih zrnaca (hemolizom).[2][3][4][5][6][7][8]

Reference[uredi - уреди | uredi izvor]

  1. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  2. Hillmen, Young, Schubert, P, N, J et al. (2006). "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria". N Engl J Med 355 (12): 1233–1243. PMID 16990386. doi:10.1056/NEJMMoa061648. 
  3. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21;355(12):1233-43. PMID 16990386
  4. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ: Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996 Dec;33(17-18):1389-401. PMID 9171898
  5. Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R: FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008 Sep;13(9):993-1000. Epub 2008 Sep 10. PMID 18784156
  6. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007 Nov;25(11):1256-64. PMID 17989688
  7. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). "DrugBank 3.0: a comprehensive resource for omics research on drugs". Nucleic Acids Res. 39 (Database issue): D1035–41. PMC 3013709. PMID 21059682. doi:10.1093/nar/gkq1126.  edit
  8. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic acids research 36 (Database issue): D901–6. PMC 2238889. PMID 18048412. doi:10.1093/nar/gkm958.  edit

Literatura[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).